Since December 2019, the SARS-CoV-2 (2019-nCoV) has raised global concerns due to its fast speed of spread and high-contamination rate, making all the hospitals, research institutes, and pharmaceutical companies anxious to find effective approaches to control it.
As a reliable partner providing biotechnology solutions and products, Creative Biolabs has urgently gathered all available resources to help accelerate relevant projects as far as possible, and ultimately capable of providing comprehensive research-use therapeutic antibodies targeting SARS-CoV-2. The catalog contains antibodies targeting N protein, S1/S2 protein, receptor binding domain (RBD) of S protein of 2019-nCOV, etc. Those antibodies mainly come from hosts like human, mouse, and rabbit, various in isotypes, and applicable to common lab tests, such as biosensors, dot, ELISA.
Recent studies have unveiled that the spike (S) glycoprotein on the surface of coronavirus SARS and SARS-CoV-2 shares similar structure which presents significance to both host specificity and viral infectivity. Therefore, applying anti SARS-CoV S antibodies to learn the binding of SARS-CoV-2 S protein with ACE2 reveals research significance. Later studies have proved S protein as a crucial target of vaccine design. Among the various products, anti-SARS-CoV S therapeutic antibody (CR3022), a clone mAb is significantly demanded.
The engineered therapeutic antibodies available at Creative Biolabs are in bulk stock and can get delivered as soon as possible with the help of a team of order handling specialists, intending to ensure timeliness, and help with customers’ programs effectively. All of them are qualified with the following features:
• High affinity
• High specificity and low off-target activity
• Low or no immunogenicity
• Endotoxin free
“We are confident with the incoming success of defeating COVID-19,” said the head of Creative Biolabs. It’s definite that the join of Creative Biolabs will add impetus to the research procedures of COVID-19 therapeutics. More information about the antibodies is accessible at https://www.creativebiolabs.net.
Set up in 2004, Creative Biolabs has won itself the position of a leading solution provider in the field of antibody discovery and products, serving for global research institutes such as universities and hospitals, and pharmaceutical companies.
Having been dedicated for years, Creative Biolabs is fully capable of providing satisfactory products based upon its high-end hybridoma development and phage display platforms, including antibody/peptide libraries, biosimilar cell lines, chimeric antigen receptor (CAR) products, antibody-drug conjugates (ADCs) to engineered antibodies, therapeutic antibodies, single-domain antibodies, bispecific antibodies and intrabodies.